This definition appears rarely
See other definitions of PPY
Samples in periodicals archive:
Dr. Deng - Hello and thank you for this very informative discussion. I have a question about patient year risk from the perspective of forecasting long term outcome. If a clinical study of a patient group with a fixed risk rate over time has documented 1 event per 100 patient years, what is the probability that a new patient with similar circumstances will have an event after 1 year? Is it 1%? How about after 10 years? Is it 10% or actually lower? I'm trying to compare to something more tangible like flipping a coin, where the probability is not 100% after two tosses, but does increase over time, but I'm not knowledgeable enough of the math behind this type of forecasting.
A rate of events per 100 patient year measures the intensity of the events over time for the underlying population with the events. For example, there were 6 patients who had hypertension events; and the duration of the events were 50, 60, 70, 80, 90, 100 days respectively. One way to calculate the rate of hypertension per 100 patient year for this population is as follows.
The National Institute for Health and Care Excellence (NICE), which assesses the cost-effectiveness of drugs for NHS use, issued draft guidance demanding more information from Alexion to explain the price tag of £340,200 per adult patient per year.
Other thrombotic events (eg, myocardial infarction, cerebrovascular accident, transient ischemic attack) have occurred in clinical trials at an annualized rate of less than 0. 04 events per patient year of PROCRIT® therapy. These trials were conducted in adult patients with CRF (whether on dialysis or not) in whom the target hematocrit was 32% to 40%. However, the risk of thrombotic events, including vascular access thrombosis, was significantly increased in adult patients with ischemic heart disease or congestive heart failure receiving PROCRIT® therapy with the goal of reaching a normal hematocrit (42%) as compared to a target hematocrit of 30%.
6 million per patient, a new record for pricey modern medicines. Up to this point in time, Alexion Pharmaceuticals’ orphan drug Soliris, which costs about $410,000/patient/year, has been the most expensive orphan drug in the world. The commerical rollout of Glybera is expected in late 2013.
Raz and Stamm reported a significant reduction in UTI among postmenopausal women using 0. 5 mg of estriol cream vaginally every night for 2 weeks and then twice a week for 8 months compared with those using a placebo (0. 5 vs. 5. 9 episodes per patient-year, P < 0. 001). Eriksen has shown a similar beneficial prophylactic effect with the use of an estradiol-releasing vaginal ring (Estring, Pharmacia & Upjohn) compared with a placebo vaginal ring.
7, & 11. 8 Total Medicare expenditures for hemodialysis totaled nearly $17 billion in 2006, while costs for peritoneal dialysis approached $1 billion and those for transplant reached 1. 8 billion, just under 10 percent of total dollars spent. Expenditures per patient year.